Clinicopathologic characterization of plasma cell neoplasms with IGH :: CCND3
American Journal of Clinical Pathology · 2026
DOI: 10.1093/ajcp/aqag080 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Clinical Pathology, 2026. Verfasst von Nandan Padmanabha und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States. Hauptthemen laut MEDLINE: Neoplasms, Plasma Cell, Cyclin D3, Immunoglobulin Heavy Chains. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben.
Abstract (Originalsprache)
Objectives
Plasma cell neoplasms (PCNs) harboring IGH::CCND3 (t(6;14)) are rare (<1% of PCNs). We sought to study these cases, as they have not been studied as a distinct entity, and their clinicopathologic features are not well characterized.
Methods
Cytogenetics databases were searched for positive IGH::CCND3 interphase fluorescence in situ hybridization (FISH) results in plasma cell neoplasms. We analyzed the clinical, morphologic, immunophenotypic, and cytogenetic features of these cases and evaluated the utility of cyclin D3 immunohistochemistry (IHC) for identifying these neoplasms.
Results
Sixteen patients were identified, presenting with multiple myeloma (n = 9), monoclonal gammopathy of undetermined significance (n = 3), smoldering myeloma (n = 2), plasma cell leukemia (n = 1), and amyloid light chain amyloidosis (n = 1). Median age at diagnosis was 68.9 years. Most cases showed lymphoplasmacytoid morphology (63%, 10/16), with frequent CD20 expression (53%, 8/15) and aberrant expression of CD56 (71%, 10/14) and CD117 (69%, 9/13). Monosomy 13 was the most frequent concurrent cytogenetic abnormality (50%, 7/14). Cyclin D3 IHC showed nuclear expression in plasma cells in all tested patients (11/11). Background erythroid precursors and megakaryocytes also showed variable positivity. When performed as a dual immunostain with CD138, cyclin D3 served as a highly sensitive and specific method for detecting these neoplastic plasma cells.
Conclusions
IGH::CCND3 PCNs frequently exhibit lymphoplasmacytoid features and CD20 expression, resembling the more common t(11;14) PCNs. Cyclin D3 IHC is an effective surrogate for the t(6;14) translocation in PCNs. We recommend using cyclin D3 IHC in the workup of PCNs with lymphoplasmacytoid morphology but negative cyclin D1 to appropriately trigger reflex FISH testing in positive cases and rescue them from the “partner-negative” category.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States.
- Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
- Division of Hematology, Stanford University, Palo Alto, CA, United States.
ORCID-Profile: Phillip D Michaels
Zitieren
APA
Padmanabha, N., Sperling, A. S., Morgan, E. A., Michaels, P. D., & Sadigh, S. (2026). Clinicopathologic characterization of plasma cell neoplasms with IGH :: CCND3. American Journal of Clinical Pathology. https://doi.org/10.1093/ajcp/aqag080
Vancouver
Padmanabha N, Sperling AS, Morgan EA, Michaels PD, Sadigh S. Clinicopathologic characterization of plasma cell neoplasms with IGH :: CCND3. American Journal of Clinical Pathology. 2026. doi:10.1093/ajcp/aqag080
BibTeX
@article{Padmanabha2026,
author = {Padmanabha, Nandan and Sperling, Adam S and Morgan, Elizabeth A and Michaels, Phillip D and Sadigh, Sam},
title = {Clinicopathologic characterization of plasma cell neoplasms with IGH :: CCND3},
journal = {American Journal of Clinical Pathology},
year = {2026},
doi = {10.1093/ajcp/aqag080}
}
EUVIMED